UCB has comfortably exceeded its target of €6bn in sales for 2024 with its five newly launched growth drivers headed by Bimzelx tripling their combined sales to more than €1.3bn.
The Belgium-headquartered group has been reflecting on a strong year for launches, especially Bimzelx (bimekizumab), its IL-17A and IL-17F inhibitor...